Ferrobotic swarms enable accessible and adaptable automated viral testing

Haisong Lin, Wenzhuo Yu, Kiarash A. Sabet, Michael Bogumil, Yichao Zhao, Jacob Hambalek, Shuyu Lin, Sukantha Chandrasekaran, Omai Garner, Dino Di Carlo () and Sam Emaminejad ()
Additional contact information
Haisong Lin: UCLA
Wenzhuo Yu: UCLA
Kiarash A. Sabet: UCLA
Michael Bogumil: UCLA
Yichao Zhao: UCLA
Jacob Hambalek: UCLA
Shuyu Lin: UCLA
Sukantha Chandrasekaran: UCLA
Omai Garner: UCLA
Dino Di Carlo: UCLA
Sam Emaminejad: UCLA

Nature, 2022, vol. 611, issue 7936, 570-577

Abstract: Abstract Expanding our global testing capacity is critical to preventing and containing pandemics1–9. Accordingly, accessible and adaptable automated platforms that in decentralized settings perform nucleic acid amplification tests resource-efficiently are required10–14. Pooled testing can be extremely efficient if the pooling strategy is based on local viral prevalence15–20; however, it requires automation, small sample volume handling and feedback not available in current bulky, capital-intensive liquid handling technologies21–29. Here we use a swarm of millimetre-sized magnets as mobile robotic agents (‘ferrobots’) for precise and robust handling of magnetized sample droplets and high-fidelity delivery of flexible workflows based on nucleic acid amplification tests to overcome these limitations. Within a palm-sized printed circuit board-based programmable platform, we demonstrated the myriad of laboratory-equivalent operations involved in pooled testing. These operations were guided by an introduced square matrix pooled testing algorithm to identify the samples from infected patients, while maximizing the testing efficiency. We applied this automated technology for the loop-mediated isothermal amplification and detection of the SARS-CoV-2 virus in clinical samples, in which the test results completely matched those obtained off-chip. This technology is easily manufacturable and distributable, and its adoption for viral testing could lead to a 10–300-fold reduction in reagent costs (depending on the viral prevalence) and three orders of magnitude reduction in instrumentation cost. Therefore, it is a promising solution to expand our testing capacity for pandemic preparedness and to reimagine the automated clinical laboratory of the future.

Date: 2022
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41586-022-05408-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:611:y:2022:i:7936:d:10.1038_s41586-022-05408-3

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-022-05408-3

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().